The refinement in transfusion techniques and graft manipulation made hematopoietic stem cell transplantation (HSCT) across different ABO/RH blood types a trivial procedure. 1 Major ABO incompatibility is defined by the presence of naturally occurring anti-A and/or anti-B in a recipient of a graft containing cells expressing the A and/or B antigen. Major ABO incompatibility poses a greater risk of acute hemolytic reaction than minor ABO incompatibility, which exists when there are naturally occurring anti-A and/or anti-B antibodies in the graft being infused in a recipient whose red cells express A and/or B. Even though transplantation between individuals with different Rh antigens is common, the risk of hemolytic reactions is negligible due to the absence of naturally occurring antibodies against antigens from the Rh group.
Passenger lymphocyte syndrome (PLS) is a recently recognized entity characterized by the infusion of a graft containing competent lymphocytes sensitized against a given blood type and causing delayed hemolysis. The syndrome has been initially described within the ABO system and can be separated from hemolysis caused by minor ABO incompatibility based on the delayed onset, typically 1 to 2 weeks after transplant. This time interval is believed to correspond to the terminal maturation of the passenger lymphocytes into antibody-producing plasma cells. Factors associated with PLS after allogeneic HSCT are reduced intensity conditioning, peripheral blood grafts (as opposed to bone marrow) and graft-versus-host disease prophylaxis without methrotrexate. 2 Even though PLS is commonly due to anti-A or anti-B antibodies, occurrence of PLS due to alloantibodies directed to other blood groups is possible and has been reported earlier. [3] [4] [5] We report a case of self-limited anti-RhD PLS in a RhD þ recipient of a RhDÀ graft from a donor previously sensitized for the RhD antigen, presumably from a transfusion of packed red blood cells.
A 58-year-old man with history of severe coronary artery disease presented with myeloid blastic phase of chronic myelogenous leukemia. He received initial treatment with dasatinib and subsequently imatinib achieving a complete hematologic and cytogenetic response. Six months after the original diagnosis he received a fully matched allogeneic peripheral blood HSCT from his 56-year-old brother. The patient ABO/Rh type was O RhD þ and the donor A RhDÀ. The donor had a history of a motor vehicle accident 8 years prior, requiring emergent transfusion of blood products. Before the transplantation, the donor had a positive screen for irregular antibodies, further specified as anti-RhD.
The
þ cells were infused without any immediate transfusional reaction. Cyclosporin and mofetil mycophenolate were used for graft-versus-host disease prophylaxis. The patient had an uneventful course until day þ 8 when he developed sudden decrease in hemoglobin, low-grade fever, hemoglobinuria and laboratory tests consistent with intravascular hemolysis (Figure 1 ). Direct antiglobulin test was positive in the anti-IgG phase and negative in the anti-C3D phase. Antibody screen revealed an anti-RhD IgG. This constellation of findings supports the diagnosis of anti-RhD PLS.
As the patient erythropoiesis (RhD þ ) was predicted to be gradually replaced by the donor's (RhDÀ), we opted to provide only supportive care with aggressive hydration and transfusion of O RhDÀ red cell units. The patient received 12 units of red cells between days þ 8 and day þ 15 with subsequent stabilization of hemoglobin levels and near normalization of hemolysis tests. Neutrophil engraftment was documented on day þ 10 and platelet engraftment on day þ 12. On day þ 15, the patient's blood typing was interpreted as O RhDÀ, reflecting the predominance of transfused red cells. The patient has not required transfusion of red cells since day þ 15 and blood typing on day þ 60 was A RhDÀ, reflecting donor-derived erythropoiesis. The patient did not experience any further complication and is in molecular remission 5 months after the transplant with bone marrow chimerism showing 100% donor hematopoiesis. As expected, the anti-RhD antibody can still be detected.
The incidence of non-ABO red blood cell alloimmunization after allogeneic HSCT ranges from 1 to 9%, 6 but it is not always associated with clinically significant hemolysis. Even though anti-RhD is the most frequently reported alloantibody to develop after HSCT, well-documented cases of anti-RhD PLS are scarce. The present case has several of the characteristics that have been linked to PLS, namely use of peripheral blood graft (due to the relatively high lymphocyte content), reduced intensity conditioning and lack of methrotrexate in the GVHD prophylaxis regimen. Hemolysis from PLS can be persistent in the setting of mixed chimersim 7 and the present case illustrates that fast engraftment and complete chimerism rapidly causes cessation of the manifestations of hemolysis and requirement for red cells transfusion.
Although additional immunosupression has been used by others in the management of PLS after HSCT, 8, 9 it may be toxic and not necessary. As the process is self-limited by the extinction by hemolysis of recipient red cells expressing the target antigen, close monitoring, aggressive hydration and transfusion of red cell units negative for the target antigen may suffice. Indeed, improvement of the hemolytic process by immunological manipulations claimed in prior reports may reflect the natural history of this condition rather than a true therapeutic benefit. 
